MINNEAPOLIS, June 14 /PRNewswire-FirstCall/ -- MedicalCV, Inc. (BULLETIN BOARD: MDCV) , http://www.medcvinc.com/ , a cardiovascular surgery device manufacturer, announced that it will be presenting today, Tuesday, June 14, 2005 at 3:35 p.m., at Medtech Insight's "Investment In Innovation (In3): A Preview of Early-Stage Medical Technology Companies" Conference, taking place June 14-15, 2005 at The Palace Hotel in San Francisco, CA.
Marc P. Flores, president and chief executive officer of MedicalCV Inc. will be presenting and will discuss the Company's technologies and applications for the treatment of atrial fibrillation; clinical references; and marketing strategy.
This two-day event will highlight emerging medical technology companies. The meeting is expected to draw an attendance of over 400 senior executives from the investment community and major medical technology, biopharmaceutical, biotech, and other companies.
"We are honored to have this opportunity to present our story of repositioning, redirecting and growing MedicalCV into the atrial fibrillation market. This conference allows us to meet with members of the financial community and potential business partners," commented Mr. Marc Flores.
Management will be available to meet with interested parties and the media to answer questions. To schedule a meeting, please contact Traci Christensen at headquarters, phone (651) 452-3000 or via email at
Medtech Insight, a division of Windhover Information Inc., is a leading provider of business information and market intelligence for the medical technology marketplace. To register for the "Investment In Innovation" conference or for more information on Medtech Insight, please call Kristy Grimes at 480-985-9512, e-mail
About MedicalCV, Inc.
MedicalCV, Inc., a cardiovascular surgery device manufacturer, focuses on the development and introduction of products designed to improve patient outcomes through the early treatment of cardiovascular disorders and disease, specifically products used by cardiac surgeons to ablate cardiac tissue as a potential means to treat atrial fibrillation. The Company's core technology is the ATRILAZE Surgical Ablation System for use in cardiac tissue ablation procedures in open-heart surgery. The Company acquired this technology in August 2003 and received its FDA 510(k) clearance in November 2004. The ATRILAZE(TM) system is being utilized for concomitant open-heart surgical procedures. The Company's common stock is traded on the OTC Bulletin Board under the symbol "MDCV."
For further information on MedicalCV, Inc., please visit http://www.medcvinc.com/ .
You may register to receive MedicalCV's future press releases and to be added to the Company's distribution list by visiting: http://www.roiny.com/form.php .
MedicalCV, Inc. Contact: Investor Relations Contact:
John H. Jungbauer ROI Group Associates, Inc.
Vice President, Finance & CFO Robert Giordano / Sarah Shepard
Phone 651.452.3000 President / Vice President
© 2005 PR Newswire
